OOSLOH: Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"

Sponsor

University Hospital, Lille (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05495802

Collaborator

Lille University Hospital Emergence Fund (Other)

5,000

Enrollment

120

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Improving the effectiveness of cancer treatments makes it possible to lengthen patient survival. It is therefore important to ensure that the quality of life is also maintained by reducing pain and handicap.

Some cancers tend to spread to the bone. The bone locations of cancer can weaken the bone and lead to complications such as fractures, pain, or compression of neurological structures.

To avoid such complications, weekly multidisciplinary meetings (MM) bring together specialists (oncologists, rheumatologists, cancer surgeons, radiologists, radiotherapists, etc.) to discuss the files of patients with bone lesions from cancer. They offer specific treatments adapted to each patient to treat or reduce the risk of complications. The OOSLOH study aims to collect clinical, biological, and imaging data from patients for whom a discussion took place in bone dedicated MM. Based on these data, epidemiological studies could be carried out to better understand the clinical factors leading cancer to colonize bone. But also to determine the factors making it possible to prevent or better treat bone complications and improve the quality of life of patients. This study does not require any examinations or additional visits to the patient

Condition or Disease	Intervention/Treatment	Phase
Bone Metastases

Study Design

Study Type:

Observational

Anticipated Enrollment :

5000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"

Anticipated Study Start Date :

Dec 1, 2022

Anticipated Primary Completion Date :

Nov 1, 2032

Anticipated Study Completion Date :

Dec 1, 2032

Outcome Measures

Primary Outcome Measures

Percentage of alive patients [through study completion, an average of 10 years]

Secondary Outcome Measures

Percentage of patients without bone disease recurrence [within one year after the multidisciplinary meeting]
Time to bone disease recurrence [through study completion, an average of 10 years]
Number of bone recurrence Number of bone recurrence [At each presentation of the patient file's to the MM,on average every week]
Epidemiological datas [At the first presentation of patient's file to the MM, on average every week]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient aged 18 or over,
Patient whose file is presented to the OOSLOH MM and who has not objected to the use of his non-nominative clinical, biological and imaging data
Social insured patient

Exclusion Criteria:

Patient who died before presentation to OOSLOH MM,
Minor patient,
Patient objecting to the use of their data for research purposes,
Patient unable to express his right to object to his participation in the study.